Loading organizations...
§ Private Profile · Sha Tin, New Territories, Hong Kong
Biopharmaceutical company offering CMC platform technology, cell line development, and cell culture media optimization for drug development.
Great Bay Bio is a biopharmaceutical company based in Tai Po New Town, Hong Kong, that leverages AI, big data, and automation to offer CMC platform technology services, cell line development, and cell culture media optimization for drug development. The company provides its bioprocessing solutions to pharmaceutical partners, aiming to address the long timelines and high costs associated with innovative drug development. To date, Great Bay Bio has raised a total of $28.8 million in funding through its Series B stage and maintains a team of 21-50 employees. It has deepened strategic collaboration with Chime Biologics and supported a client in securing US government approval for a drug developed using its tools for clinical trials. Great Bay Bio was founded in 2019 by Kingsley Leung and Dr. Michael Chan.
Great Bay Bio has raised $25.0M across 2 funding rounds.
Great Bay Bio has raised $25.0M in total across 2 funding rounds.
Great Bay Bio has raised $25.0M across 2 funding rounds. Most recently, it raised $15.0M Pre-Series B in September 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 15, 2022 | $15M Series A Plus | Tiger Jade Capital | AEF Greater BAY Area Fund, Vectr Ventures | Announced |
| Dec 1, 2021 | $10M Series A | Proxima Ventures | — | Announced |
Great Bay Bio has raised $25.0M in total across 2 funding rounds.
Great Bay Bio's investors include Tiger Jade Capital, AEF Greater Bay Area Fund, Vectr Ventures, Proxima Ventures.